A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese

American Journal of Hypertension

Volumn 26, Issue 12, 2013, Pages 1428-1436

  Liu, Ming ^a   Li, Yan ^a   Citterio, Lorena ^b   Huang, Qi Fang ^a   Zeng, Wei Fang ^a   Sheng, Chang Sheng ^a   Wei, Fang Fei ^a   Dong, Qian ^a   Li, Ge Le ^a   Kang, Yuan Yuan ^a   Zhang, Lu ^a   Xu, Ting Yan ^a   Li, Jing Jing ^a   Song, Jie ^a   Manunta, Paolo ^b   Wang, Ji Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

ABCB1; Albuminuria; Blood pressure; Chronic kidney disease; Genetic polymorphism; Hypertension; Renal function

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT;

ABCB1 GENE; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; CHINESE; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PHENOTYPE; PRIORITY JOURNAL; PULSE PRESSURE; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

EID: 84890518128     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt126     Document Type: Article

References (36)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-7738.
2. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997; 77:284-289.
3. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528.
4. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
5. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. MDR1 gene polymorphism and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53:526-534.
6. Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
7. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-Transplant recipients. Transplantation 2004; 78:21-25.
8. García M, Macías RM, Cubero JJ, Benítez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013; 69:385-393.
9. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20:2468-2480.
10. Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009; 20:1404-1415.
11. Von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-Adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47:1048-1052.
12. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, van Gelder T. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011; 33:178-184.
13. Metalidis C, Lerut E, Naesens M, Kuypers DR. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 2011; 91:1098-1102.
14. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-1511.
15. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a longterm follow-up. Clin Pharmacol Ther 2010; 88:95-100.
16. Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, Bianchi G, Manunta P. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003; 21:1475-1481.
17. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 2004; 279:33306-33314.
18. Li Y, Staessen JA, Li LH, Gao PJ, Thijs L, Brand E, Brand-Herrmann SM, Zhu DL, Wang JG. Blood pressure and urinary sodium excretion in relation to the A-1984G adrenomedullin polymorphism in a Chinese population. Kidney Int 2006; 69:1153-1158.
19. Li LH, Li Y, Wen Y, Wang JG. Anthropometric and metabolic phenotypes in relation to the ADRA2B deletion/insertion polymorphism in Chinese population. J Hypertens 2008; 26:2161-2167.
20. Hu BC, Li Y, Li FH, Zhang Y, Sheng CS, Fan HQ, Wang JG. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphism in Chinese. J Hypertens 2011; 29:501-508.
21. Sheng CS, Liu M, Zeng WF, Huang QF, Li Y, Wang JG. Four-limb blood pressure as predictors of mortality in elderly Chinese. Hypertension 2013; 61:1155-1160.
22. Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, Nelson RG, Van Deventer M, Wang HY, Zuo L, Zhang YL, Levey AS. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int 2011; 79:555-562.
23. Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y, Xu J, Huang S, Wang L, Huang W, Wang M, Xu G, Zhang L, Zuo L, Wang H; Chinese eGFR Investigation Collaboration. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant 2013; 28:641-651.
24. Hennekens CH, Buring JE. Basic concepts. In: Mayrent SL (ed), Epidemiology in Medicine, 1st edn. Little, Brown: Boston, 1987, pp. 87-93.
25. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44:1049-1060.
26. Manov I, Bashenko Y, Hirsh M, Iancu TC. Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells. Basic Clin Pharmacol Toxicol 2006; 99:213-224.
27. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331:1675-1679.
28. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996; 28:S14-S19.
29. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801-1808.
30. Zhang WX, Chen B, Zhang W, Chen N, Yu ZC, Cai WM. Effect of MDR1 gene polymorphism on progression of end-stage renal disease. Acta Pharmacol Sin 2007; 28:579-583.
31. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM. Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance MDR gene expression. J Biol Chem 1993; 268:27127-27132.
32. Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res 2001; 61:1693-1698.
33. Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens 2009; 27:9-18.
34. Tripodi G, Citterio L, Kouznetsova T, Lanzani C, Florio M, Modica R, Messaggio E, Hamlyn JM, Zagato L, Bianchi G, Staessen JA, Manunta P. Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am J Hypertens 2009; 22:357-363.
35. Bignami E, Casamassima N, Frati E, Lanzani C, Corno L, Alfieri O, Gottlieb S, Simonini M, Shah KB, Mizzi A, Messaggio E, Zangrillo A, Ferrandi M, Ferrari P, Bianchi G, Hamlyn JM, Manunta P. Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients. Crit Care Med 2013; 41:744-755.
36. Bochud M, Eap CB, Maillard M, Johnson T, Vollenweider P, Bovet P, Elston RC, Bergmann S, Beckmann JS, Waterworth DM, Mooser V, Gabriel A, Burnier M. Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. BMC Med Genomics 2008; 1:21.